Amantadine(AM) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Amantadine (AM) antibodies (anti-Amantadine, anti-AM) and diagnostic hapten-carrier conjugates BSA-Amantadine (AM), OVA-Amantadine (AM), KLH-Amantadine (AM) antigens for Infectious disease/Neurodegenerative diseases AM detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Neurodegenerative diseases diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-169-Ag01BSA-Amantadine(AM)$756.00
GMP-SMT-169-Ag02OVA-Amantadine(AM)$756.00
GMP-SMT-169-Ab01Anti-human Amantadine(AM) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-169-Ab02Anti-human Amantadine(AM) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Amantadine(AM)

Cat No.GMP-SMT-169-Ag01
Product NameBSA-Amantadine(AM)
TargetAmantadine(AM)
Expression platformSynthetic
Bioactivity validationAmantadine(AM) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AM level test of Infectious disease/Neurodegenerative diseases (Influenza A, Parkinson's disease) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Amantadine(AM) / OVA-Amantadine(AM) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Amantadine(AM)

Cat No.GMP-SMT-169-Ag02
Product NameOVA-Amantadine(AM)
TargetAmantadine(AM)
Expression platformSynthetic
Bioactivity validationAmantadine(AM) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AM level test of Infectious disease/Neurodegenerative diseases (Influenza A, Parkinson's disease) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Amantadine(AM) / OVA-Amantadine(AM) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Amantadine(AM) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-169-Ab01
Product NameAnti-human Amantadine(AM) mouse monoclonal antibody (mAb)
TargetAmantadine(AM)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationAmantadine(AM) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amantadine(AM) antibodies in AM level test of Infectious disease/Neurodegenerative diseases (Influenza A, Parkinson's disease) and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Amantadine(AM) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Amantadine(AM) human monoclonal antibody (mAb)

Cat No.GMP-SMT-169-Ab02
Product NameAnti-human Amantadine(AM) human monoclonal antibody (mAb)
TargetAmantadine(AM)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationAmantadine(AM) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amantadine(AM) antibodies in AM level test of Infectious disease/Neurodegenerative diseases (Influenza A, Parkinson's disease) and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Amantadine(AM) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. Detailed Overview of Amantadine and Its Diagnostic Significance

    Amantadine hydrochloride, a synthetic adamantane derivative, exhibits a broad spectrum of pharmacological activities, prominently including antiviral and antiparkinsonian properties. As an antiviral agent, it primarily interferes with the replication cycle of the influenza A virus, notably by blocking the M2 proton channel, thereby preventing viral uncoating and subsequent replication in host cells. In the realm of neurology, Amantadine enhances dopaminergic function, which is beneficial in managing Parkinson's disease symptoms and drug-induced extrapyramidal reactions by releasing dopamine from nerve endings and inhibiting its reuptake.

    The molecular specificity and pharmacodynamic profile of Amantadine make it an invaluable target for in vitro diagnostic testing, particularly in therapeutic drug monitoring (TDM). The development of high-affinity antibodies against Amantadine, alongside the creation of small molecule competitive antigens, forms the cornerstone of immunoassays designed to accurately quantify Amantadine concentrations in biological samples. These assays are vital for evaluating drug efficacy, adjusting dosages to avoid toxic levels, and ensuring patient adherence to treatment plans. Furthermore, the ability to monitor Amantadine levels is instrumental in research and clinical practice for understanding drug metabolism variations across populations, which can influence treatment outcomes.

    2. Importance of Measuring Amantadine in Clinical Practice

    The quantification of Amantadine concentrations in patient samples is paramount for several interconnected reasons in clinical pharmacology and personalized medicine:

    Therapeutic Drug Monitoring (TDM)

    TDM is an essential clinical practice that ensures drug levels remain within a therapeutic range that maximizes efficacy while minimizing adverse effects. Given Amantadine's narrow therapeutic index, precise measurement is crucial to avoid underdosing, which may lead to therapeutic failure, or overdosing, which can result in toxicity, including neurological and cardiac side effects.

    Patient Compliance and Pharmacokinetic Variability

    Regular monitoring of Amantadine levels can serve as an indicator of patient compliance, a significant factor in the successful management of chronic conditions such as Parkinson's disease. Moreover, individual differences in drug metabolism — influenced by genetic factors, age, renal function, and interactions with other medications — necessitate personalized dose adjustments. Quantitative analysis of Amantadine facilitates these adjustments, ensuring optimal therapeutic outcomes.

    Resistance Management and Personalized Medicine

    In the context of antiviral therapy, monitoring drug levels is crucial for preventing the emergence of drug-resistant strains of the influenza A virus, which can occur when sub-therapeutic drug concentrations allow for viral mutation and selection. Additionally, TDM supports the principles of personalized medicine by enabling healthcare providers to tailor treatment strategies based on the unique metabolic and pharmacokinetic profiles of individual patients, thereby enhancing the efficacy and safety of Amantadine therapy.

    In summary, the precise measurement of Amantadine through in vitro diagnostic methods plays a pivotal role in clinical decision-making. It supports therapeutic drug monitoring, ensures patient adherence, accommodates pharmacokinetic variability, aids in resistance management, and underpins personalized medicine approaches. This comprehensive approach to drug monitoring underscores the importance of advanced diagnostic tools and methodologies in optimizing patient care and therapeutic strategies.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.